Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma.

Bibliographic Details
Title: Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma.
Authors: Liu Z; Department of Neurosurgery, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.; Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.; The Third School of Clinical Medicine, Southern Medical University, Shenzhen, Guangdong, China.; Department of Neurosurgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China., Zhou J; Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.; The Third School of Clinical Medicine, Southern Medical University, Shenzhen, Guangdong, China., Yang X; Department of Neurosurgery, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.; The Third School of Clinical Medicine, Southern Medical University, Shenzhen, Guangdong, China.; Department of Neurosurgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China., Liu Y; Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China., Zou C; School of Medicine, Life and Health Sciences, The Chinese University of Hong Kong (Shenzhen), Shenzhen, Guangdong, China., Lv W; Department of Neurosurgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China., Chen C; Department of Neurosurgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China., Cheng KK; Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, China., Chen T; Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.; The Third School of Clinical Medicine, Southern Medical University, Shenzhen, Guangdong, China., Chang LJ; Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China. c@szgimi.org., Wu D; Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China. wudinglan123@smu.eud.com.; The Third School of Clinical Medicine, Southern Medical University, Shenzhen, Guangdong, China. wudinglan123@smu.eud.com., Mao J; Department of Neurosurgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China. myw921@yahoo.com.
Source: Molecular cancer [Mol Cancer] 2023 Jan 09; Vol. 22 (1), pp. 3. Date of Electronic Publication: 2023 Jan 09.
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE
Database: MEDLINE Complete
Full text is not displayed to guests.
Description
ISSN:1476-4598
DOI:10.1186/s12943-022-01711-9